|
|
Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/1137
|
| Title: | Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda |
| Authors: | Tumwine, Lynnette K
Agostinelli, Claudio
Campidelli, Cristina
Othieno, Emmanuel
Wabinga, Henry
Righi, Simona
Falini, Brunangelo
Piccaluga, Pier Paolo
Byarugaba, Wilson
Pileri, Stefano A |
| Keywords: | Lymphomas
Non Hodgkin lymphomas
Uganda
Immunophenotypes
Immunohistochemical
Immunology
Cells |
| Issue Date: | Dec-2009 |
| Publisher: | BioMed Central |
| Citation: | Tumwine, L.K, Agostinelli, C., Campidelli, C., Othieno, E., Wabinga,H. , Righi, S., Falini, B., Piccaluga, P.P., Byarugaba, W. & Pileri, S.A. (2009). Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda BMC Clinical Pathology, 9(11) |
| Abstract: | Background: Non Hodgkin lymphomas are the most common lymphomas in Uganda. Recent studies
from developed countries have shown differences in survival for the different immunophenotypes. Such
studies are lacking in Africa where diagnosis is largely dependent on morphology alone. We report
immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients in Kampala,
Uganda.
Methods: Non Hodgkin lymphoma tissue blocks from the archives of the Department of Pathology,
Makerere University College of Health Sciences, Kampala, Uganda, from 1991-2000, were sub typed using
haematoxylin and eosin, Giemsa as well as immunohistochemistry. Using tissue micro array, 119 biopsies
were subjected to: CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a, CD138, Bcl-6, Bcl-2, IRTA-1,
MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, and Ki-67/Mib1. Case notes were retrieved for: disease stage,
chemotherapy courses received and retrospective follow up was done for survival.
Results: Non Hodgkin B cell lymphomas comprised of Burkitt lymphoma [BL] (95/119) diffuse large B cell
lymphoma (19/119), mantle cell lymphoma (4/119) and precursor B lymphoblastic lymphoma (1/119).
For Burkitt lymphoma, good prognosis was associated with receiving chemotherapy, female gender and
CD30 positivity. Only receiving chemotherapy remained significant after Cox regression analysis. Diffuse
large B cell lymphomas with activated germinal centre B cell (GCB) pattern (CD10+/-, BCL-6+/-, MUM+/
-, CD138+/-) had better survival (98.4 months; 95% CI 89.5 -107.3) than the others (57.3 months; 95% CI
35.5 - 79.0) p = 0.027 (log rank test).
Conclusions: Activated GCB diffuse large B cell lymphoma had a better prognosis than the others. For
Burkitt lymphoma, not receiving chemotherapy carried a poor prognosis. Availability of chemotherapy in
this resource limited setting is critical for survival of lymphoma patients. |
| URI: | http://hdl.handle.net/123456789/1137 |
| ISSN: | 1472-6890 |
| Appears in Collections: | Research Articles (Health-Sciences)
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| tumwine-lynnette-k-chs-res.pdf | | 240Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
